Related Experiment Video
Updated: Jun 16, 2026

Development of a Larval Zebrafish Infection Model for Clostridioides difficile
Published on: February 14, 2020
Expect the unexpected: fungemia caused by uncommon Candida species in a Turkish University Hospital
Sehnaz Alp1, Dolunay Gulmez2, Rıza Can Kardas3
1Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Hacettepe University, 06100, Sihhiye, Ankara, Turkey. alpsehnaz@gmail.com.
Abstract:
Fungemia caused by uncommon Candida species (UCS) (other than C.albicans, C.glabrata, C.parapsilosis, C.tropicalis, C.krusei) is a rare but emerging threat with their potential to exhibit reduced susceptibility or resistance to antifungal agents. We identified 25 patients with UCS fungemia (9 C.kefyr, 8 C.lusitaniae, 4 C.dubliniensis, 2 C.guilliermondii, 1 C.pelliculosa, 1 C.rugosa) through January 2011 and August 2018. Echinocandins were the most common administered agents, followed by fluconazole. Overall mortality was 44%. Echinocandins and voriconazole showed sufficient activity against all tested isolates. High fluconazole MICs among C.guilliermondii, C.pelliculosa, and C.rugosa were determined. MIC value of C.pelliculosa was above the epidemiological cut-off proposed for fluconazole.
Insights
Uncommon Candida species (UCS) fungemia presents a growing risk due to antifungal resistance. Echinocandins and voriconazole demonstrated effectiveness, but high fluconazole resistance was noted in certain UCS strains.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Fungemia caused by uncommon Candida species (UCS) is an emerging threat.
- UCS may exhibit reduced susceptibility or resistance to antifungal agents.
- This poses a challenge in treating invasive fungal infections.
Purpose of the Study:
- To analyze the clinical characteristics and outcomes of patients with UCS fungemia.
- To evaluate the in vitro antifungal susceptibility patterns of UCS isolates.
- To assess the efficacy of commonly used antifungal agents against UCS.
Main Methods:
- Retrospective analysis of 25 patients with UCS fungemia from January 2011 to August 2018.
- Identification of UCS including C.kefyr, C.lusitaniae, C.dubliniensis, C.guilliermondii, C.pelliculosa, and C.rugosa.
- Antifungal susceptibility testing (MIC determination) for various antifungal agents.
Main Results:
- Overall mortality rate was 44%.
- Echinocandins and voriconazole showed sufficient activity against all tested UCS isolates.
- High fluconazole minimum inhibitory concentrations (MICs) were observed for C.guilliermondii, C.pelliculosa, and C.rugosa, with C.pelliculosa exceeding the epidemiological cut-off.
Conclusions:
- UCS fungemia is associated with significant mortality.
- Echinocandins and voriconazole are effective against a broad range of UCS.
- Fluconazole resistance is a concern for specific UCS, necessitating careful treatment selection.
Related Concept Videos
Candidiasis
Cryptococcal Meningitis
Urine Studies II: Urine Culture and Sensitivity Test
Fungal Phylum Microsporidia
Fungal Group Zygomycota